Yarkın ÖZENLİ, Önder TUĞAL, Cengiz CENGİSİZ

Paliperidone palmitate-induced sialorrhoea

Atipik antipsikotiklere ilişkin ekstrapiramidal, metabolik ve kardiyak yan etkiler bildirilmiştir. Paliperidona bağlı siyalore bildiren az sayıda kaynağa rastlanmasına karşın paliperidon palmitata bağlı siyalore bildiren kaynağa rastlanmamıştır. Bu yazımızda kliniğimize başvuran ve paliperidon palmitat başladığımız bir hastada gelişen siyalore yan etkisi sunulmuştur

Paliperidon palmitata bağli siyalore

Extrapyramidal, metabolic, and cardiac side effects were reported for atypical antipsychotics; although a few resources show paliperidone-induced sialorrhea, there are no resources that show paliperidone palmitate-induced sialorrhea. In this paper, we present the paliperidone palmitate-induced sialorrhea side effects of a patient who applied on our clinic

PDF

___

1. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a metaanalysis. Lancet. 2009;373:31-41.
2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.
3. FDA Approves New Drug for Schizophrenia [Internet] [cited 2015 Nov 26] Available from: http://www.fda.gov/NewsEvents/Newsroom/Pres sAnnouncements/2006/ucm108812.htm
4. Taylor D, Paon C, Kapur S. The Maudsley Prescribing Guidelines. 10th Edition. London: Informa Healthcare, 2009;15.
5. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd Edition. New York, NY, Cambridge University Press, 2008.
6. Hough D, Lindenmayer J-P, Gopal S, Melkote R, Lim P, Herben V et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1022–31.
7. Vermeule A, Wouters A. Patent of dosing regimen association with long acting injectable paliperidone esters. 2009;US20090163519A.
8. Keith SJ, Kane JM, Turner M, Conley RR, Nasrallah HA. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry. 2004;65:120–11.
9. Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M et al. A controlled, evidence-based trial of paliperidone palmitate, a longacting injectable antipsychotic, in schizophrenia. Neuropsychopharmacol 2010;35:2072–82.
10. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-torelapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116:107-17.
11. Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin. 2010;26:377-330.
12. Megens AA, Awouters FHL. In vivo pharmacological profile of 9-hydroxy-risperidone the major metabolite of the novel antipsychotic risperidone. Drug Dev Res. 1994;33:399-412.
13. Invega® Product Information. Janssen Pharmaceuticals. [Internet] [cited 2015 Dec 16] Available from: http://www.janssencns.com/invegaprescribing-information,
14. Bavikatte G, Sit PL, Hassoon A. Management of drooling of saliva. British Journal of Medical Practitioners 2012;5:a507.
15. Cree A, Mir S, Fahy T. A review of thetreatment options for clozapine-induced hypersalivation. Psychiatr Bull. 2001;25:114-16.
16. Ben-Areyh H, Jungeman T, Szargel R, Klein E, Laufer D. Salivary flow-rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data. Biol Psychiatry. 1996;39:946-49.
17. Invega Sustenna® Product Information. Janssen Pharmaceuticals. [Internet] [cited 2015 Dec 16] Available from: http://www.invegasustenna.com
18. Goldstein JM. The new generation of antipsychotic drugs: How atypical are they?. Int J Neuropsychopharmacol. 2000; 3:339–49.
19. Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol. 1995;15:19-23.
20. van Beijsterveldt LE, Geerts RJ, Leysen JE, Megens AA, Van den Eynde HM, Meuldermans WE, Heykants JJ. Regional brain distribution of risperidone and its active metabolite 9- hydroxyrisperidone in the rat. Psychopharmacol (Berl). 1994;114:53–62.
21. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebocontrolled study. Schizophr Res. 2007;93:117-30.
22. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115:260–7.
23. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70:1-46.
24. Stahl SM. The prescriber’s guide. Stahl’s essential psychopharmacology. 4th Edition. New York, NY: Cambridge University Press. 2011;446.
25. Harrington CA, English C. Tolerabilitity paliperidone: a meta-analysis of randomized, controlled trials. Int Clin Psychopharmacol. 2010;25:334-41.
26. Bell G, Emslie-Smith D, Paterson C. Mouth, oesophagus and swallowing. In: Bell G, EmslieSmith D, Paterson C (editors) Textbook of Physiology. New York: Churchill Livingstone. 1980;36-42.
27. Szabadi E, Tavernor S. Hypo- and hyper-salivation induced by psychoactive drugs. Incidence, mechanisms and therapeutic implications. CNS Drugs.1999;11:449-66.
28. Freudenreich O. Drug-induced sialorrhea. Drugs Today (Barc). 2005;41:411–8.
29. Berlan M, Montarstruc J, Lafontan M. Pharmacological prospects for alpha 2 adrenoceptor antagonist therapy. Trends Pharmacol Sci. 1992;13:277-82.
30. Bai YM, Lin CC, Chen JY, Liu WC. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double blind, placebocontrolled, cross-over study. J Clin Psychopharmacol. 2001;21:608-11.
31. Praharaj SK, Arora M, Gandotra S. Clozapineinduced sialorrhea: pathophysiology and management strategies. Psychopharmacol (Berl). 2006;185:265–73.
32. Gajwani P, Franco-Bronson K, Tesar GE. Risperidone-induced sialorrhea. Psychosomatics. 2001;42:276.
33. Panagiotidis PT, Fountoulakis KN, Siamouli M, Magiria S, Iacovides A, Kaprinis G. Risperidoneinduced sialorrhea responsive to biperiden treatment. Schizophr Res. 2007;93:410–1.
34. Liang CS, Liao WC, Yang FW, Ho PS. Risperidoneinduced sialorrhea: dose-related ? Pharmacopsychiatry. 2010;43:282-3.
35. Usta MG, Tufan AE, Cüceloğlu EA. Diphenhydramine use in the treatment of risperidone-induced sialorrhea. J Child Adolesc Psychopharmacol. 2012;22:254-5.
36. Perkins DO, McClure RK. Hypersalivation coincident with olanzapine treatment. Am J Psychiatry. 1998;155:993–4.
37. Hori T, Makabe K, Nemoto K, Asada T. Hypersalivation induced by olanzapine with fluvoxamine. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:758–60.
38. Allen S, Hoffer Z, Mathews M. Quetiapine-induced hypersalivation. Prim Care Companion J Clin Psychiatry. 2007;9:233.
39. Praharaj SK, Jana AK, Sinha VK. Aripiprazoleinduced sialorrhea. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33:384–5.
40. Kılınç S, Hergüner A, Hergüner S. Aripiprazoleinduced sialorrhea responsive to diphenhydramine treatment. J.Child .Adolesc Psychopharmacol. 2015;25:1-2.
41. Richardson C, Kelly DL, Conley RR. Biperiden for excessive sweating from clozapine. Am J Psychiatry. 2001;158:1329-30.
42. Copp PJ, Lament R, Tennent TG. Amitriptyline in clozapine induced sialorrhoea. Br J Psychiatry. 1991;159:166.
43. Praharaj SK, Arora M. Amitriptyline for clozapineinduced nocturnal enuresis and sialorrhea. Br J Clin Pharmacol. 2007;63:128-9.
44. Hall H, Ögren SO. Effects of antidepressant drugs on different receptors in brain. Eur J Pharmacol. 1981;70:393-407.
45. Stegemann S, Gosch M, Breitkreutz J. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm. 2012;430:197-206.
46. Nair S, Saeed O, Shahab H, Sedky K, Garver D, Lippmann S. Sudden dysphagia with uvular enlargement following the initiation of risperidone which responded to benztropine: was this an extrapyramidal side effect? Gen Hosp Psychiatry. 2001;23:231-2.
47. Stewart JT. Dysphagia associated with risperidone therapy. Dysphagia. 2003;18:274-5.
48. Mendhekar DN, Agarwal A. Paliperidone-induced dystonic dysphagia. J Neuropsychiatr Clin Neurosci. 2010;22:e37.
49. McCarthy RH, Terkelsen KG. Esophageal dysfunction in two patients after clozapine treatment. J Clin Psychopharmacol. 1994;14:281-3.
50. Varghese ST, Balhara YP, George SA, Sagar R. Risperidone and dysphagia. J Postgrad Med. 2006;52:327–8.
51. Brahm NC, Fast GA, Brown RC. Risperidone and Dysphagia in a developmentally disabled woman. Prim Care Companion J Clin Psychiatry. 2007;9:315– 6.
52. Sagar R, Varghese ST, Balhara YP. Dysphagia due to olanzapine, an antipsychotic medication. Indian J Gastroenterol. 2005;24:37-8.
53. Kohen I, Lester P. Quetiapine-associated dysphagia. World J Biol Psychiatry. 2009;10:623-5.
54. Armstrong D, Ahuja N, Lloyd AJ. Quetiapine-related dysphagia. Psychosomatics. 2008;49:450–2.
55. Lin TW, Lee BS, Liao YC, Chiu NY, Hsu WY. High dosage of aripiprazole-induced dysphagia. Int J Eat Disord. 2012; 45:305-6.